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To study the activity of metronidazole on persisting tubercle bacilli, BALB/c mice were infected with
Mycobacterium tuberculosis and, after 14 days, treated with isoniazid (H) or rifampicin (R) or isoniazid
+ rifampicin (HR) for 2 months. An untreated group and a group treated with metronidazole (M)
alone served as controls. At the end of 2 months, M was added to the H, R, and HR regimen in half
the mice, and the treatment was continued for 1 more month in all mice. At the end of treatment, no
viable organisms were detected in the lung or spleen of mice treated with HR or HRM regimens. In
contrast, compared to the mice treated with R alone, the log10 colony forming units (cfu) of mice
treated with RM were lower by 1.84 and 0.52 in the lung and spleen, respectively. Similarly, compared
to the H group, the log10 cfu were lower by 0.67 in the spleen of mice treated with HM, and no
additional effect due to M was seen in the lung. Three months after stopping treatment, viable
organisms were isolated from both the organs of all the groups. However, the log10 cfu in the lung and
spleen for the groups with metronidazole were below the log10 cfu for the respective single or 2 drug
groups, except the log10 cfu in the lung for the RM group. These findings suggest that metronidazole,
given with bactericidal drugs such as rifampicin and isoniazid may be of value in eliminating
persisting tubercle bacilli, but further studies are warranted.
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It is well recognized that tubercle bacilli have the
ability of sequestering themselves to stay in a
dormant state in the host. None of the currently used
antituberculosis drug regimens completely eliminate
this population and the possibility of endogenous
reactivation at a later date always remains. In various
controlled clinical trials using short course
chemotherapeutic (SCC) regimens of 6-8 months’
duration, almost 90 per cent culture conversion was
usually observed at the end of 2 months among
patients infected with drug sensitive organisms.
But when the treatment period was shortened to 3-
4 months relapse occurred in 20-25 per cent of
patients with initially drug sensitive organisms
suggesting that this treatment schedule perhaps
produced a small population of ‘dormant’ or
‘persisting’ bacilli1. Mitchison2, in his hypothesis of
‘special bacterial populations’, highlighted the
importance of dormant bacilli and their role in the
occurrence of relapse. With the recent spurt in the
incidence oftuberculosis in HIV-infected individuals,
there is resurgence of interest in this population3,4.
These dormant bacteria have never been isolated
and characterized. The evidence for their existence
comes from animal models, and in vitro experiments5-7.
In the ‘Cornell model’ of murine tuberculosis,
mycobacterial DNA was demonstrated8 14 wk after
stopping treatment. Although no bacteria could be
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isolated from cultures of the lung or spleen by
conventional methods, heavy inocula of spleen
homogenates into uninfected mice resulted in the
development of disease8.. These results suggested the
presence of a dormant bacterial population.
Wayne and colleagues9,10 using an in vitro system,
demonstrated the presence of dormant Mycobacterium
tuberculosis in the oxygen-free layer of undisturbed
cultures. These bacilli  not only resisted the
bactericidal effect of anaerobiosis but also exhibited
partial or complete resistance to the bactericidal effect
of isoniazid or rifampicin. They also showed for the
first time, that metronidazole (M) could act on these
bacilli9. More recently, Wayne and Hayes11, using a
better in vitro model, demonstrated a sequential
downward shift into one or both of two nonreplicating
stages, corresponding to microaerophilic and
anaerobic persistence. We used a murine model of
tuberculosis to simulate conditions as similar to the
above to study the effect of metronidazole on
presumably ‘persisting’ bacilli. Infected mice were
treated with the bactericidal drugs rifampicin and
isoniazid, either alone or in combination, for 2
months to generate a population of ‘persisting’ bacilli
which were then treated for 1 month with regimens
with or without metronidazole.
Material & Methods
M. tuberculosis strain : A pretreatment clinical isolate
(Ts 51476) of  M. tuberculosis ,  sensitive to
streptomycin (S), isoniazid (H), rifampicin (R),
ethambutol (EMB) and pyrazinamide (PZA), was
used in this experiment. Prior to use, the minimum
inhibitory concentration (MIC) for this strain to these
drugs was again determined on Lowenstein-Jensen
(LJ) medium using standard methods12. The strain
was also passaged in mice before use.
Drugs  :  Isoniazid  was obtained f rom Bayer
Leverkusen, Germany, rifampicin from Sigma
Chemical Company, and metronidazole powder from
Rhone Poulenc (India) Ltd.
Infection of mice : A total of 102 BALB/c outbred
female mice aged 1-2 months, obtained from the
National Institute of Nutrition, Hyderabad, were
infected with the M. tuberculosis strain (Ts 51476)
by injecting through the tail vein, a suspension
containing 106 organisms in 0.2 ml of distilled water
prepared from 3 wk old growth on LJ medium’?. The
number of organisms in the bacterial suspension was
adjusted using a Thoma counter (Thomas Scientific,
NJ, USA). The viable count (VC) set up from this
suspension showed that it contained 1.9 x 106 colony
forming units (cfu) in 0.2 ml. Three mice were
sacrificed immediately after infection, and three
others 14 days thereafter. Their spleen and lung were
removed aseptically and VC was set up as follows.
The whole organs were transferred to a sterile
grinding tube and ground in 2 ml of sterile distilled
water using a teflon-coated grinding rod. From this
homogenate as the neat suspension, and from five,
serial 10-fold dilutions, cultures were set up on
duplicate slopes of LJ by inoculating 10 µl per slope,
which were then incubated at 37°C for 4 wk and the
number of colonies were counted to determine the
cfu in the organs14.
Treatment : Treatment was started on day 14 post
infection. The 96 mice were divided into 8 groups of
12 animals each. The first group did not receive any
treatment and served as the control. Four groups of
mice were treated 6 days a week for 3 months with
metronidazole (M), isoniazid (H), rifampicin (R) and
isoniazid and rifampicin (HR), respectively. In the
remaining 3 groups, the drugs H, R and HR
respectively, were administered for the initial 2
months and M was added to this treatment schedule
during the third month (MH, MR, MHR). R was
always administered 30 min before the other drugs.
The drugs were administered by oral gavage in 0.2
ml of 0.1 per cent agar. The dosages were as follows :
M 100 mg/kg14, R 10 mg/kg, and H 25 mg/kg15. The
drugs were prepared at one time point and stored at
- 70° C until used.
Three mice from each group were sacrificed at the
end of 1, 2 and 3 months of treatment and also at the
end of 3 months after stopping treatment. Their spleen
and lungs were removed aseptically and cfu in these
organs was determined as described above.
Statistical methods : Significance of the data was
calculated using McNemer’s test.
Results
In the lung and spleen of infected mice 5.00 and
4.95 log10 cfu of M. tuberculosis respectively, were
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present at the start of treatment. At the end of the
second month of treatment, the log10 cfu of M.
tuberculosis in the lung was the lowest in mice treated
with R alone (0.97) followed by HR (1.00) and H
(1.64) (Table I). In spleen, the corresponding values
were 1.09, 0.67 and 2.07, respectively (Table II).
Compared to the untreated control group, there was
no reduction in log10 cfu of mice treated with M
alone, either in the lung or spleen.
At the end of the third month of treatment, in the
lung of mice treated with R alone the log10 cfu of M.
tuberculosis increased to 1.84 from the second month
count of 0.97. This was because M. tuberculosis was
isolated from the lungs of 2 of the 3 mice sacrificed
in the R group after the third month of treatment. On
drug susceptibility testing of these strains, one was
found to be resistant to R (MIC>128) and the other
was sensitive. At this time point, M. tuberculosis
could not be isolated from the lungs of any of the 3
mice which were treated with M in addition to R
(RM group). The log10 cfu in the lungs of mice
treated with H and HM were 0.67 and 1.04,
Table 1. log10 colony forming units of M. tuberculosis in lung
(Data are mean ± SE)
Group Months after start of treatment 3 months
after
1 2 3 stopping treatment
Control’ 7.19±1.02 5.3±0.54 3.88±0.47 5.24±0.73
M 5.34±1.45 6.44±0.88 4.48±0.41 3.71±0.34
H 3.88±0.33 1.64±0.67 0.67±0.54 3.4±1.4
R 0.98±0.80 0.97±0.79 1.84±0.79 1.09±0.89
HR 2.12±1.03 1.00±0.58 0 1.98±1.14
HM 1.64+±0.67 1.04**±0.85 1.83±1.50
RM 0.97+±0.79 0** 2.50±0.86
HRM 1.00+±0.58 0** 1.34±1.09
*At 2 wk after infection, the mean log10 cfu was 5.00
+Same values as for isoniazid (H), rifampicin (R) and HR respectively, since metronidazole was added only at 2 months
**1 month after start of metronidazole (M)
Table II. log10 colony forming units of M. tuberculosis in spleen
(Data are mean ± SE)
Group Months after start of treatment 3 months
after
I 2 3 stopping treatment
Control* 7.17±0.91 4.49±0.40 3.48±0.35 3.47±0.42
M 5.98±1.15 5.73±1.21 3.78±0.28 3.13±0.35
H 4.52±0.13 2.07±0.84 1.80±0.73 3.19±0.29
R 2.39±0.23 1.09±0.89 1.49±0.62 1.44±0.59
HR 2.84±0.43 0.67±0.54 0 1.64±0.67
HM 2.07+±0.84 1.13**±0.92 0.98±0.80
RM 1.09+±0.89 0.97**±0.79 0.87±0.71
HRM 0.67+±0.54 0** 0.87±0.71
*At 2 wk after infection, the mean log10 cfu was 4.95
+Same values as for isoniazid (H), rifampicin (R) and HR respectively, since metronidazole was added only at 2 months
** 1 month after start of metronidazole (M)
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respectively, at this time point. In the spleen, the
log10 cfu of M. tuberculosis was lower in the RM
group (0.97) compared to R group (1.49), and again
in the HM group (1.13) compared to the H group
(1.80). None of the above differences were
statistically significant. In both lung and spleen, no
detectable count was obtained at the end of 3 months
in mice treated with HR, and HRM.
At 3 months after stopping treatment,  M.
tuberculosis was isolated from both the lung and
spleen of all the groups, including the groups in
which M. tuberculosis was undetectable at the end of
3 months of treatment (Tables I and II). However, in
these groups, the log10 cfu of M. tuberculosis was
lower in groups with M compared to the respective
single or two drug groups in both lung and spleen,
except in the RM in which the log10 cfu in the lung
was 2.50 compared to 1.09 with R alone.
Discussion
T h e  c h e m o t h e r a p y  o f  t u b e r c u l o s i s  w a s
revolutionised by the development of the concept of
SCC which utilised combinations of drugs that were
effective against different populations of bacilli.
However, despite effective regimens being available,
relapses continue to occur in many studies. It has
been suggested that the persisters, which are not
s u s c e p t i b l e  t o  a n y  o f  t h e  r e g u l a r l y  u s e d
antituberculous drugs, are responsible for these
relapses, probably due to ‘endogenous reactivation’
of tuberculous disease. The currently used BCG
vaccine, while possibly affording protection against
fresh infection, is incapable of protecting against
breakdown into disease. In this situation also, it has
been suggested that the breakdown occurs when
dormant bacilli find an opportune time to multiply
and activate the disease process. However, despite a
large body of evidence that has been generated to
implicate the role of the ‘dormant bacilli’16,17, more
information is required with regard to drugs or
regimens which would be effective against them. It
has been shown in vitro that metronidazole, a
commonly used drug, can act on nonreplicating
bacilli’, but to our knowledge, ours is the first in vivo
experiment aimed towards evaluating the activity of
metronidazole in combination with other drugs on
persisting tubercle bacilli.
In the present study, metronidazole showed an
additive effect with rifampicin in reducing the log10
cfu of M. tuberculosis in both the lung and spleen of
mice at the end of 3 months of treatment. When
metronidazole was combined with isoniazid this
effect was observed only in the spleen. Similar
observations in vitro were reported by Wayne and
Sramek9. In their study, when tubercle bacilli under
anaerobic incubation were exposed to these drugs,
metronidazole did not exhibit additive effect when
combined with  isoniazid  but  enhanced the
bactericidal effect 10-fold when combined with
rifampicin. Evidence for rifampicin activity on
semidormant bacilli was also observed by Wayne
and Hayes11 in their model of sequential shift down
to anaerobiosis in which only 12- 19 per cent of bacilli
survived when 28 days old semidormant bacilli were
exposed to rifampicin alone.
In our murine model it was observed that in mice
treated with metronidazole in combination with
r i fampicin  or  r i fampicin  and isoniazid ,  M.
tuberculosis became undetectable in the lung at the
end of 3 months, while they were still present in the
lung of mice treated with metronidazole and
isoniazid. Treatment with metronidazole and
rifampicin for the duration used in the present study,
was not able to reduce the M. tuberculosis counts in
the spleen to an undetectable level even though they
were lower than those in the spleen of mice treated
with rifampicin alone. A longer duration of treatment
with this combination may be required to sterilise the
organs.
Our findings that metronidazole exhibited an
additive effect against tubercle bacilli when combined
with rifampicin, suggests that metronidazole may
have value in eliminating persisters and thus in
reducing relapse rates. The period at which
metronidazole is to be added to isoniazid and
rifampicin requires to be determined. Considering
the limited number of animals tested at each time
point, the small differences observed and the limited
duration of treatment with metronidazole in the
present study, further studies on larger numbers of
animals at each time point and a longer follow up are
necessary to fully assess the activity of metronidazole
with other anti-tuberculosis drugs at different
concentrations and at different &rations of treatment.
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The use of metronidazole may be beneficial in
individuals who are HIV positive and who need to
receive antituberculosis therapy as chemoprophylaxis
to prevent endogenous reactivation of any dormant
tubercle bacilli4. Besides, metronidazole would also
help them by containing concomitant opportunistic
parasitic and other anaerobic infections. Further
studies are necessary to evaluate this novel approach
of management of tuberculosis infection in this
special group.
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